André Oberdiek
About André Oberdiek
André Oberdiek is the Director & Team Leader Pricing Strategy and Execution at Bristol Myers Squibb in Boudry, Switzerland, with extensive experience in payer strategy, pharmaceutical commercialization, and team leadership.
Current Position at Bristol Myers Squibb
André Oberdiek is the Director & Team Leader, Pricing Strategy and Execution at Bristol Myers Squibb. He is based in Boudry, Neuchâtel, Switzerland. In his current role, André oversees the creation and implementation of pricing strategies, ensuring the company remains competitive and compliant in the pharmaceutical market.
Previous Experience at Celgene
Before joining Bristol Myers Squibb, André worked at Celgene as the Director of Value, Access, and Pricing. He held this position from 2018 to 2021 in Boudry, Kanton Neuenburg, Schweiz. During his tenure, he focused on maximizing the value of Celgene's products through strategic pricing and market access initiatives.
Career at Roche
André Oberdiek has an extensive background with Roche, having served in two significant roles. From 2014 to 2017, he was the Senior International Payer Strategy Leader in Basel und Umgebung, Schweiz. Prior to this, he served as the International Payer Strategy Leader from 2012 to 2014 in Basel Area, Switzerland. His roles involved shaping global payer strategies to ensure the successful market entry and lifecycle management of pharmaceutical products.
Education and Academic Background
André Oberdiek holds a Master of Business Administration (MBA) with a focus on Finance from FOM Hochschule für Oekonomoe & Management (2005-2007). He has also studied at the University of Bristol as an exchange student in 2000, and at Université Grenoble Alpes where he was an ERASMUS student in Political Science and Government (1997-1998). Furthermore, he completed his Magister Artium in Political Science, History, and Economics at Leibniz Universität Hannover (1995-2000).
Professional Skills and Expertise
André Oberdiek has a robust skill set in developing payer evidence, business forecasting planning, and lifecycle management. He has led multiple cross-functional teams, emphasizing the development of high-potential individuals. Well-versed in the German Payer Landscape, he leverages these connections for strategic pharmaceutical advantages. Additionally, André is a Verified Inclusion Partner (VIP), focusing on Diversity & Inclusion competencies. His specialization includes process and operations improvement, personalized healthcare, project/change management, and the commercialization of drugs, including small molecules, biologics, cell therapy, and treatments for rare diseases.